Drug intelligence / Profile preview

STMD-001

Development stage: Preclinical
Lead developer: Sentrimed

Overview

STMD-001 is a preclinical-stage therapeutic candidate being developed by Sentrimed for the treatment of oncology indications. The drug is designed to target or leverage contact normalization, a cellular communication process where non-transformed cells inhibit the proliferation and migration of adjacent transformed tumor cells. By restoring or enhancing contact normalization, STMD-001 aims to prevent tumor progression and metastasis.

Beyond the preview

Go deeper on STMD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STMD-001.

Explore the full profile